JP2007527409A5 - - Google Patents

Download PDF

Info

Publication number
JP2007527409A5
JP2007527409A5 JP2006534354A JP2006534354A JP2007527409A5 JP 2007527409 A5 JP2007527409 A5 JP 2007527409A5 JP 2006534354 A JP2006534354 A JP 2006534354A JP 2006534354 A JP2006534354 A JP 2006534354A JP 2007527409 A5 JP2007527409 A5 JP 2007527409A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
group
inverse agonist
adrenergic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006534354A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007527409A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/033157 external-priority patent/WO2005034871A2/en
Publication of JP2007527409A publication Critical patent/JP2007527409A/ja
Publication of JP2007527409A5 publication Critical patent/JP2007527409A5/ja
Pending legal-status Critical Current

Links

JP2006534354A 2003-10-09 2004-10-08 β−アドレナリンインバースアゴニストを用いて気道疾患を治療する方法 Pending JP2007527409A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51025003P 2003-10-09 2003-10-09
US55579704P 2004-03-23 2004-03-23
PCT/US2004/033157 WO2005034871A2 (en) 2003-10-09 2004-10-08 Methods for treating diseases and conditions with inverse agonists

Publications (2)

Publication Number Publication Date
JP2007527409A JP2007527409A (ja) 2007-09-27
JP2007527409A5 true JP2007527409A5 (https=) 2008-01-17

Family

ID=34437322

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006534354A Pending JP2007527409A (ja) 2003-10-09 2004-10-08 β−アドレナリンインバースアゴニストを用いて気道疾患を治療する方法

Country Status (7)

Country Link
US (1) US9539221B2 (https=)
EP (2) EP1677778A2 (https=)
JP (1) JP2007527409A (https=)
AU (2) AU2004279438A1 (https=)
CA (2) CA2544611A1 (https=)
IL (1) IL174765A0 (https=)
WO (2) WO2005034871A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
ES2335498T3 (es) 2003-03-10 2010-03-29 Nycomed Gmbh Nuevo proceso para la preparacion de reflumilast.
CA2558126A1 (en) * 2004-03-17 2005-09-29 Sosei R&D Ltd. The treatment of inflammatory disorders and pain using beta-aminoalcohols
JP2007536350A (ja) * 2004-05-10 2007-12-13 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 肺気腫の予防又は治療のためのロフルミラストの使用
WO2006044694A2 (en) 2004-10-15 2006-04-27 Palo Alto Investors Methods and compositions for treating a disease condition in a subject
US8663694B2 (en) 2005-03-16 2014-03-04 Takeda Gmbh Taste masked dosage form containing roflumilast
AU2006269944A1 (en) * 2005-07-19 2007-01-25 Inverseon, Inc. Improved pharmacokinetic profile of beta-adrenergic inverse agonists for the treatment of pulmonary airway diseases
CA2807854A1 (en) * 2009-08-12 2011-02-17 Pulmosonix Pty Ltd Determining dynamic airway response in a subject
EP3513787A1 (en) * 2011-01-10 2019-07-24 Invion, Inc Use of beta-adrenergic inverse agonists for smoking cessation
US11382513B2 (en) 2016-11-08 2022-07-12 Palo Alto Investors Methods and compositions for treating a condition in a subject
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
JP7682097B2 (ja) 2019-03-27 2025-05-23 キュラセン セラピューティクス インコーポレイテッド ベータアドレナリンアゴニスト及びそれを使用する方法
CA3161376A1 (en) 2019-12-18 2021-06-24 Anthony P. FORD Methods for improving neurological diseases and disorders
WO2022192252A1 (en) * 2021-03-09 2022-09-15 Chronic Airway Therapeutics Limited Use of nadolol to treat chronic obstructive pulmonary disease by blockage of the arrestin-2 pathway
WO2023250334A1 (en) * 2022-06-21 2023-12-28 Curasen Therapeutics, Inc. Compositions and methods involving isolated compounds
WO2023250332A1 (en) * 2022-06-21 2023-12-28 Curasen Therapeutics, Inc. Compositions and methods involving isolated compounds
CN116199596B (zh) * 2023-03-06 2025-03-25 梯尔希（南京）药物研发有限公司 一种特布他林代谢物的制备方法
AU2024234602A1 (en) * 2023-03-13 2025-10-30 Chronic Airway Therapeutics Limited USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US36547A (en) * 1862-09-23 Improvement in locks
US4428926A (en) * 1981-12-18 1984-01-31 Key Pharmaceuticals, Inc. Sustained release propranolol system
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
US4769372A (en) * 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US5116867A (en) * 1989-06-30 1992-05-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services D-propranolol as a selective adenosine antagonist
US5352680A (en) * 1992-07-15 1994-10-04 Regents Of The University Of Minnesota Delta opioid receptor antagonists to block opioid agonist tolerance and dependence
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5633259A (en) * 1992-09-21 1997-05-27 United Biomedical, Inc. Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction
US20010006967A1 (en) * 1992-09-21 2001-07-05 Stanley M. Crain Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists
USRE36547E (en) 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US5472943A (en) * 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
US6673558B1 (en) * 1992-09-30 2004-01-06 Richard G. Lanzara Drug compositions to prevent desensitization of cellular receptors
US6593094B2 (en) * 1992-09-30 2003-07-15 Richard G. Lanzara Compositions to enhance the efficacy and safety of bio-pharmaceutical drugs
US5597699A (en) * 1992-09-30 1997-01-28 Lanzara; Richard G. Method for determining drug compositions to prevent desensitization of cellular receptors
US5585348A (en) * 1993-02-10 1996-12-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia
AU2068797A (en) * 1996-01-29 1997-08-20 Edward Mendell Co. Inc. Sustained release excipient
JPH10251147A (ja) 1997-03-06 1998-09-22 Akira Matsumori 炎症性疾患の予防・治療剤
US6284800B1 (en) * 1997-03-13 2001-09-04 Baker Norton Pharmaceuticals, Inc. Methods and compositions for treatment of asthma
US6541209B1 (en) * 1997-04-14 2003-04-01 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
US6420541B1 (en) * 1998-04-14 2002-07-16 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
TR200002059T2 (tr) * 1998-01-16 2001-01-22 Takeda Chemical Industries, Ltd. Devamlı salınan bileşim, üretim yöntemi ve kullanımı.
US6653086B1 (en) * 1998-04-14 2003-11-25 Arena Pharmaceuticals, Inc. Endogenous constitutively activated G protein-coupled orphan receptors
US6107324A (en) * 1998-04-14 2000-08-22 Arena Pharmaceuticals Inc. 5-HT2A receptor inverse agonists
EP1086102A1 (en) * 1998-06-10 2001-03-28 Arena Pharmaceuticals, Inc. Acetylcholine enhancers
US6140509A (en) * 1998-06-26 2000-10-31 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US6420563B1 (en) * 1998-07-31 2002-07-16 Arena Pharmaceuticals, Inc. Small molecule modulators of G protein-coupled receptor six
US6627632B2 (en) * 1998-12-14 2003-09-30 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
US6150393A (en) * 1998-12-18 2000-11-21 Arena Pharmaceuticals, Inc. Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors
US6194382B1 (en) * 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
US6765010B2 (en) * 1999-05-06 2004-07-20 Pain Therapeutics, Inc. Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects
CN1420929A (zh) * 2000-04-07 2003-05-28 阿瑞那制药公司 非内源性组成型活化的已知g蛋白偶联受体
AU2001292897A1 (en) 2000-09-21 2002-04-02 Richard Agustin Bond Novel therapy
SK288031B6 (sk) * 2000-10-31 2012-12-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Propellant-free liquid inhalation formulation
US7018812B2 (en) * 2000-11-03 2006-03-28 Duke University Modified G-protein coupled receptors
DE60236496D1 (de) * 2001-03-23 2010-07-08 Einstein Coll Med Verfahren zur erhöhung der analgetischen wirkung und zur verringerung der unerwünschten exitatorischen wirkungen von bimodalisch wirksamen opioidagonisten durch die hemmung von gm1-gangliosid
AU2002309196A1 (en) * 2001-06-26 2003-01-08 Decode Genetics Ehf. Nucleic acids encoding olfactory receptors
US7149574B2 (en) * 2003-06-09 2006-12-12 Palo Alto Investors Treatment of conditions through electrical modulation of the autonomic nervous system

Similar Documents

Publication Publication Date Title
JP2007527409A5 (https=)
ES2315425T3 (es) Compuestos de amonio cuaternario y su uso como agentes antimuscarinicos.
JP2013531056A5 (https=)
CN101432268A (zh) 作为β2肾上腺素受体激动剂的4-(2-氨基-1-羟乙基)酚衍生物
JP2008501705A5 (https=)
JP2022519131A5 (https=)
EP2222272A1 (en) Respiratory disease treatment
MX2013009525A (es) Combinacion de glicopirrolato y un beta2-agonista.
RU2010126063A (ru) Производные 4-(2-амино-1-гидроксиэтил)фенола как агонисты в2 адренергического рецептора
CA2563302A1 (en) Combinations of glycopyrrolate and beta2 adrenoceptor agonists
RU2010108640A (ru) Новая комбинация терапевтических агентов
RU2008124833A (ru) Лечение астмы и хронического обструктивного заболевания легких с использованием тройных комбинаций
CN101657191B (zh) 包括福莫特罗和二丙酸倍氯米松的组合物在制备用于预防和/或治疗哮喘恶化的药物中的用途
JP2011517316A5 (https=)
CN106470700A (zh) 用于治疗copd的噻托溴铵、福莫特罗和布地奈德的组合
US20120029014A1 (en) 5-(2--1-hydroxyethyl)-8-hydroxyquinolin-2 (1h)-one for the treatment of lung function
US9040588B2 (en) Acetamide stereoisomer
JP2009504768A5 (https=)
JP2010538010A5 (https=)
JP2012530134A (ja) 呼吸器疾患治療における併用療法及び吸入薬剤としてのｒ型バンブテロールの使用
JP2006504768A (ja) 四級アンモニウム化合物
JP2013518061A5 (https=)
JP2006501207A5 (https=)
JP6346618B2 (ja) アクリジニウムの新規用途
JP5529740B2 (ja) カルバメート立体異性体